Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline

Description:

"Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications.

This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.

A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005-2008, when the proportion was relatively high.

Scope

- What is the current size and composition of the pharmaceutical industry pipeline and how has it changed since Q1 2015? What can we learn from this?
- The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
- What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
- What factors have been driving the increasing number of first-in-class product approvals over recent decades?
- What strategies have companies typically been pursuing with their pipeline portfolio, in terms of how diverse, specialized or innovative they have been? Specifically, what strategies have the top 25 pharmaceutical companies been following?
- What key discernible trends have appeared in the strategic consolidations landscape in the past decade and which disease areas have been most active?

Key Reasons to Purchase

This report will allow you to:
- Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process
- Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one's own strategic positioning against this backdrop
- Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications
- Make key decisions about the role of innovation within one's own pipeline portfolio

Contents:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Increasing Cost of Drug Development
2.2 Most Drugs Fail to Recuperate R&D Costs
2.3 Contracting Life Cycles for Approved Products
2.4 The Case for First-in-Class Pharmaceutical Innovation
2.5 Conclusion

3 Assessment of the Pharmaceutical Industry Pipeline
3.1 Pipeline and Clinical Trials Landscape by Therapy Area
3.2 Pipeline by Stage of Development
3.3 Pipeline by Molecule Type
3.4 Key Therapy Areas by Indication
3.4.1 Oncology
3.4.2 Infectious Diseases
3.4.3 Central Nervous System
3.4.4 Immunology
3.5 Conclusion

4 Assessment of Innovation in the Pharmaceutical Industry Pipeline
4.1 First-in-Class Innovation by Stage of Development
4.2 Key Therapy Areas by Indication
4.2.1 Oncology
4.2.2 Infectious Diseases
4.2.3 Central Nervous System
4.2.4 Immunology
4.3 Conclusion

5 Company Analysis
5.1 Conclusion

6 Deals Analysis
6.1 Licensing Deals
6.2 Co-development Deals
6.3 Mergers and Acquisitions
6.4 Capital Raising

7 Appendix
7.1 References
7.2 Contact Us
7.3 Disclaimer

1.1 List of Tables
Table 1: Trends in Clinical Trial Protocol Complexity, 2000-2011
Table 2: Pipeline Products by Therapy Area, 2015-Q1 2016
Table 3: Number of Clinical Trials Initiated by Therapy Area, 2006-2015
Table 4: Pipeline Products by Therapy Area and Stage of Development
Table 5: Pipeline Products by Therapy Area and Molecule Type, Q1 2016
Table 6: First-in-Class Pipeline Products by Therapy Area, Q1 2015-Q1 2016
Table 7: First-in-Class Oncology Pipeline Products by Indication, Q1 2015-Q1 2016
Table 8: First-in-Class Infectious Diseases Pipeline Products by Indication, Q1 2015-Q1 2016
Table 9: First-in-Class Central Nervous System Disorder Pipeline Products by Indication, Q1 2015-Q1 2016
Table 10: First-in-Class Immunology Pipeline Products by Indication, Q1 2015-Q1 2016
Table 11: Licensing Deal Value and Volume, 2006-Q1 2016
Table 12: Number of Licensing Deals by Therapy Area, 2006-Q1 2016
Table 13: Aggregate Licensing Deal Value by Therapy Area ($m), 2006-Q1 2016
Table 14: Co-development Deal Value and Volume, 2006-Q1 2016
Table 15: Co-development Deal Volume by Therapy Area, 2006-Q1 2016
Table 16: Co-development Deal Value by Therapy Area ($m), 2006-Q1 2016
Table 17: Merger and Acquisition Deal Value and Volume, 2006-Q1 2016
Table 18: Capital Raising Value and Volume, 2006-Q1 2016

1.2 List of Figures
Figure 1: US Life Expectancy by Sex, 1950-2015
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline
Web Address: http://www.researchandmarkets.com/reports/3782920/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2995</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 5990</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 8985</td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ________________________________
Job Title: ______________________________
Organisation: __________________________
Address: ______________________________
City: ________________________________
Postal / Zip Code: ______________________
Country: ______________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp